New agents in acute myeloid leukemia: Beyond cytarabine and anthracyclines

Amir T. Fathi, Judith E. Karp

Research output: Contribution to journalReview articlepeer-review


The standard therapeutic approaches for acute myeloid leukemia (AML) continue to be based on anthracyclines and cytarabine. However, the prognosis for AML remains poor, especially for patients with high-risk disease. During the past decade, promising novel agents that target DNA replication and repair, as well as cell cycling and apoptosis, have been developed and are being actively investigated in AML. Among these agents is flavopiridol, which interferes with key steps of the cell cycle and effectively promotes cell death, and voreloxin, an intercalating agent that also targets topoisomerase II. Also under clinical study in AML are oligonucleotide antisense constructs, which suppress the translation of proteins essential for leukemic blast survival and proliferation, and agents that target antiapoptotic cascades. In summary, it is hoped that novel therapies such as these will augment and/or supplant our current cytarabine- and anthracycline-based approaches, overcome active drug-resistance pathways, and eventually improve outcomes for patients with AML.

Original languageEnglish (US)
Pages (from-to)346-352
Number of pages7
JournalCurrent oncology reports
Issue number5
StatePublished - 2009

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'New agents in acute myeloid leukemia: Beyond cytarabine and anthracyclines'. Together they form a unique fingerprint.

Cite this